To identify drugs that can trigger apoptosis in KRAS-mutated NSCLC cells with TP53 mutations, we performed drug screening in H23 and H358 (TP53-mutant) cells using a custom library of kinase inhibitors consisting of 432 compounds. This evidence concerns the gene KRAS and non-small cell lung carcinoma.